Physician profile
Richard Levine
NPI 1700997988
$2,260.10
in general payments reported to CMS, 2019-2025
26 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $331 · 2021: $302 · 2022: $113 · 2023: $17.81 · 2024: $252 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.50 | 2019-2025 | |
| Apyx Medical Corporation | $334.24 | 2019 | |
| Amgen INC. | $296.71 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $193.54 | 2019-2024 | |
| Janssen Biotech, INC. | $112.82 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $111.72 | 2021-2025 | |
| Genzyme Corporation | $89.33 | 2024-2025 | |
| Lilly USA, LLC | $84.25 | 2019-2020 | |
| Leo Pharma INC. | $64.08 | 2019-2025 | Adbry |
| Almirall LLC | $58.53 | 2021-2022 | |
| Allergan, INC. | $49.38 | 2019 | |
| Pfizer INC. | $48.21 | 2019 | |
| Genentech USA, INC. | $45.69 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $37.27 | 2024 | Dupixent, Libtayo |
| Smith+Nephew, INC. | $35.40 | 2024 | Renasys Go V2 Home |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.74 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $26.66 | 2021-2022 | |
| Organon LLC | $25.23 | 2025 | Vtama |
| Ucb, INC. | $24.92 | 2019 | |
| Dermira, INC. | $23.01 | 2020 | |
| Biofrontera INC. | $20.72 | 2021 | |
| Phadia US INC. | $20.55 | 2022 | |
| Angiodynamics, INC. | $19.54 | 2019 | |
| Incyte Corporation | $17.77 | 2022 | |
| Dusa Pharmaceuticals, INC. | $17.65 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.